Dimensional Fund Advisors LP cut its holdings in shares of Organon & Co. (NYSE:OGN – Get Rating) by 1.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,484,631 shares of the company’s stock after selling 14,608 shares during the quarter. Dimensional Fund Advisors LP owned 0.58% of Organon & Co. worth $34,742,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Organon & Co. by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 29,156,417 shares of the company’s stock worth $1,018,434,000 after buying an additional 381,744 shares during the last quarter. State Street Corp increased its holdings in shares of Organon & Co. by 8.3% during the 2nd quarter. State Street Corp now owns 12,955,993 shares of the company’s stock valued at $437,265,000 after purchasing an additional 997,608 shares in the last quarter. Mawer Investment Management Ltd. increased its holdings in shares of Organon & Co. by 30.8% during the 2nd quarter. Mawer Investment Management Ltd. now owns 10,848,522 shares of the company’s stock valued at $366,137,000 after purchasing an additional 2,553,301 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Organon & Co. by 0.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 7,575,257 shares of the company’s stock valued at $177,260,000 after purchasing an additional 44,987 shares in the last quarter. Finally, Sound Shore Management Inc CT increased its holdings in shares of Organon & Co. by 0.6% during the 3rd quarter. Sound Shore Management Inc CT now owns 2,563,291 shares of the company’s stock valued at $59,981,000 after purchasing an additional 14,519 shares in the last quarter. 75.74% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Separately, Morgan Stanley cut their target price on shares of Organon & Co. from $27.00 to $24.00 and set an “equal weight” rating for the company in a report on Friday, November 4th.
Organon & Co. Stock Performance
Organon & Co. (NYSE:OGN – Get Rating) last released its quarterly earnings results on Thursday, February 16th. The company reported $0.81 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.04). Organon & Co. had a net margin of 14.85% and a negative return on equity of 118.21%. The company had revenue of $1.49 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same period in the prior year, the business posted $1.37 EPS. Organon & Co.’s revenue was down 7.4% compared to the same quarter last year. Sell-side analysts predict that Organon & Co. will post 4.43 EPS for the current year.
Organon & Co. Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 16th. Investors of record on Monday, February 27th will be paid a $0.28 dividend. The ex-dividend date is Friday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 4.65%. Organon & Co.’s dividend payout ratio is currently 31.20%.
Organon & Co. Profile
Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
- Get a free copy of the StockNews.com research report on Organon & Co. (OGN)
- Hormel Hits 2-Year Low, And The Dip Gets Bought
- Here’s Why Ross Could Soon Be Hitting All Time Highs
- The Bottom Is In For Salesforce.com
- It’s Time For A Fresh Look At The Kroger Co.
- West Fraser’s Earnings Scream Timber, Outlook Says Buy
Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN – Get Rating).
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.